by Dale Harrison | Jun 25, 2021 | Publications
“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021 Authors David J. Elzi, William E. Bauta,...
by Maria Zannes | Jun 23, 2021 | Events, Press Releases
JUNE 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, will present the Company’s discoveries in the field of cancer diagnostics and therapeutics at the RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium June 23 – 25,...
by Maria Zannes | Jun 8, 2021 | Events
Dr. Elzi will present his poster “Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” at the University of Massachusetts RNA Therapeutics Symposium: From Concept to Clinic, June 23-25, 2021. Dr. Elzi’s live presentation will...
by Dale Harrison | May 22, 2021 | Publications
“Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells” At the American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021 Authors David J. Elzi, William Bauta,...
by Maria Zannes | Mar 20, 2021 | Articles, News
Local CEO: New recommendations acknowledge that women and Black people are at higher risk than white men MARCH 19, 2021 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San-Antonio Business Journal Several major national medical...
